Nir Ayalon, MD
Interventional Cardiology · Boston, MANPI 1437470226
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Abiomed accounts for 88.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $40,821, 5.5 times the $7,397 reported in 2019.
Across 29 payments — averaging $2701.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$70K
- Abbott$7K
- Biosense Webster, Inc.$972
- Medtronic$541
What the payments were for
- Consulting fees$45,56358%
- Speaking & faculty fees$24,10031%
- Travel & lodging$7,94410%
- Food & beverage$7341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 8 | $69,663 |
| Abbott | 9 | $7,165 |
| Biosense Webster, Inc. | 8 | $972 |
| Medtronic | 4 | $541 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$30,000
- CardioMEMS HF System$6,739
- Carto 3$760
- CoreValve Evolut$391
- CARDIOMEMS$309
How this compares
$78,341 in reported general payments places this provider in the 85th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $133,148 |
| JardianceEmpagliflozin | 85 | $108,406 |
| EntrestoSacubitril/Valsartan | 31 | $45,824 |
| FarxigaDapagliflozin Propanediol | 20 | $19,071 |
| XareltoRivaroxaban | 19 | $14,735 |
| Metoprolol Succinate | 222 | $4,028 |
| Nifedipine ErNifedipine | 63 | $2,692 |
| Atorvastatin Calcium | 192 | $2,604 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $2,298 |
| Rosuvastatin Calcium | 79 | $2,051 |
| Labetalol Hcl | 13 | $1,706 |
| Torsemide | 34 | $1,041 |
| Ezetimibe | 42 | $988 |
| Amlodipine Besylate | 139 | $889 |
| Lisinopril | 100 | $807 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Boston
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.